Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design

Journal of Neuro-oncology
Richard G EversonShaan M Raza

Abstract

Surgery and radiation therapy are the standard treatment options for meningiomas, but these treatments are not always feasible. Expression profiling was performed to determine the presence of therapeutic actionable biomarkers for prioritization and selection of agents. Meningiomas (n = 115) were profiled using a variety of strategies including next-generation sequencing (592-gene panel: n = 14; 47-gene panel: n = 94), immunohistochemistry (n = 8-110), and fluorescent and chromogenic in situ hybridization (n = 5-70) to determine mutational and expression status. The median age of patients in the cohort was 60 years, with a range spanning 6-90 years; 52% were female. The most frequently expressed protein markers were EGFR (93%; n = 44), followed by PTEN (77%; n = 110), BCRP (75%; n = 8), MRP1 (65%, n = 23), PGP (62%; n = 84), and MGMT (55%; n = 97). The most frequent mutation among all meningioma grades occurred in the NF2 gene at 85% (11/13). Recurring mutations in SMO and AKT1 were also occasionally detected. PD-L1 was expressed in 25% of grade III cases (2/8) but not in grade I or II tumors. PD-1 + T cells were present in 46% (24/52) of meningiomas. TOP2A and thymidylate synthase expression increased with grade (I = 5%, II = 2...Continue Reading

References

May 1, 1996·Journal of Neurosurgery·M C Chamberlain
Sep 1, 1996·Journal of Neuro-oncology·A P Kyritsis
Apr 14, 2004·Neurology·Marc C ChamberlainSusan Groshen
Apr 22, 2006·Journal of Neuro-oncology·Marc C ChamberlainSusan Groshen
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chang-Qi ZhuUNKNOWN National Cancer Institute of Canada Clinical Trials Group Study BR.21
Apr 21, 2009·Nature Reviews. Cancer·John L Nitiss
Jun 30, 2009·Journal of Neuro-oncology·Andrew D NordenPatrick Y Wen
Aug 5, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stéphane GoutagnyMichel Kalamarides
Sep 8, 2010·Journal of Neuro-oncology·Patrick Y WenAndrew D Norden
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffRobert Penny
Aug 5, 2011·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Sumitra AnandaUNKNOWN Cooperative Trials Group for Neuro-Oncology (COGNO)
Sep 20, 2011·Computational Statistics & Data Analysis·Mulugeta GebregziabherJoyce S Nicholas
Sep 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Apostolia-Maria TsimberidouRazelle Kurzrock
Jan 22, 2013·Nature Genetics·Priscilla K BrastianosRameen Beroukhim
Feb 14, 2013·Acta Neuropathologica·David E ReussAndreas von Deimling
Jan 23, 2014·Journal of Neuro-oncology·Jeffrey J RaizerMarc Chamberlain
Mar 13, 2014·Cancer Chemotherapy and Pharmacology·Marta SimóJordi Bruna
May 23, 2014·Science Translational Medicine·Irina M ShapiroJonathan A Pachter
Jul 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Apostolia-Maria TsimberidouDonald Berry
Sep 3, 2014·Clinical Genitourinary Cancer·Sherri Z MillisNicholas J Vogelzang
Nov 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bella KaufmanSusan M Domchek
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amanda J Redig, Pasi A Jänne
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria SchwaederleRazelle Kurzrock
Nov 4, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yongli JiClaire Verschraegen
Jan 16, 2016·Journal of Neurosurgery·Wenya Linda BiIan F Dunn
Jan 31, 2016·Neuro-oncology·Malak AbedalthagafiSandro Santagata
Apr 29, 2016·Expert Review of Neurotherapeutics·E Le RhunM C Chamberlain
Aug 23, 2016·Nature Genetics·Victoria E ClarkMurat Günel
Sep 15, 2016·Brain Tumor Pathology·Sayaka YuzawaShinya Tanaka
Nov 26, 2016·Journal of Neurosurgery·Matthew R StricklandFred G Barker
Jan 17, 2017·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Efrat GelersteinTal Shahar
Apr 22, 2017·Oncotarget·Alejandra M PetrilliCristina Fernández-Valle
May 10, 2017·Neuro-oncology·Ganesh M Shankar, Sandro Santagata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.